Adding Nalbuphine for Control of Intrathecal Morphine Pruritus

Last updated: February 26, 2021
Sponsor: Minia University
Overall Status: Active - Recruiting

Phase

2

Condition

Vomiting

Rash

Hives (Urticaria)

Treatment

N/A

Clinical Study ID

NCT04589429
678-9/2020
  • Ages 18-80
  • All Genders

Study Summary

Intrathecal morphine causes intense itching which is very bothersome. Nalbuphine antagonizes this effect when given intravenously. This trial is to find out if nalbuphine added to intrathecal morphine has an effect on morphine related pruritus while still maintaining adequate analgesia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male and female patients.
  • Age 18-80yrs.
  • Elective major abdominal surgery under general anesthesia.

Exclusion

Exclusion Criteria:

  • Refusal to participate.
  • Skin or systemic disease with itching. Any condition which precludes performing spinalinjection

Study Design

Total Participants: 70
Study Start date:
October 15, 2020
Estimated Completion Date:
March 31, 2021

Study Description

The study will be performed in MiniaUniversity Hospitals, after obtaining approval from the local ethics committee. All patients will have a peripheral IV cannula 18 G inserted; standard non-invasive monitors will be applied. Patients undergoing major abdominal surgery will be divided into 2 groups to receive intrathecal morphine 300 micrograms with or without nalbuphine 1mg prior to anesthesia. General anesthesia is then given to patients.

Connect with a study center

  • anesthesia&ICU department

    Minya,
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.